[go: up one dir, main page]

PE106999A1 - Composicion de amlodipina y una estatina - Google Patents

Composicion de amlodipina y una estatina

Info

Publication number
PE106999A1
PE106999A1 PE1998000768A PE00076898A PE106999A1 PE 106999 A1 PE106999 A1 PE 106999A1 PE 1998000768 A PE1998000768 A PE 1998000768A PE 00076898 A PE00076898 A PE 00076898A PE 106999 A1 PE106999 A1 PE 106999A1
Authority
PE
Peru
Prior art keywords
statin
composition
effect
amlodipine
carotidal
Prior art date
Application number
PE1998000768A
Other languages
English (en)
Inventor
Jan Buch
Robert Andrew Donald Scott
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22011309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE106999(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE106999A1 publication Critical patent/PE106999A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE a)BESILATO DE AMLODIPINA; b)UNA ESTATINA TAL COMO SIMVASTATINA, PRAVASTATINA, RIVASTATINA, MEVASTATINA, LOVASTATINA, ENTRE OTROS; CON LA CONDICION QUE LA ESTATINA NO DEBE SER ATORVASTATINA. LA COMPOSICION TIENE UN EFECTO SINERGICO ANTIHIPERTENSOR, HIPOLIPIDEMICO, ANTIATEROSCLEROTICO Y EN EL MANEJO DEL RIESGO CARDIACO CON RESPECTO AL EFECTO DEL PRIMER Y SEGUNDO COMPONENTE POR SEPARADO. EL EFECTO ANTIATEROSCLEROTICO SE DA POR EL LENTO PROGRESO DE LAS PLACAS ATEROSCLEROTICAS EN LAS ARTERIAS CORONARIAS, CAROTIDAS Y EN EL SISTEMA ARTERIAL PERIFERICO
PE1998000768A 1997-08-29 1998-08-24 Composicion de amlodipina y una estatina PE106999A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5755597P 1997-08-29 1997-08-29

Publications (1)

Publication Number Publication Date
PE106999A1 true PE106999A1 (es) 1999-11-06

Family

ID=22011309

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000768A PE106999A1 (es) 1997-08-29 1998-08-24 Composicion de amlodipina y una estatina

Country Status (36)

Country Link
US (1) US20020025981A1 (es)
EP (1) EP1003507A1 (es)
JP (1) JP2001514224A (es)
KR (1) KR20010022385A (es)
CN (1) CN1117566C (es)
AP (1) AP1207A (es)
AR (1) AR017514A1 (es)
AU (1) AU744982B2 (es)
BG (1) BG104076A (es)
BR (1) BR9811558A (es)
CA (1) CA2296726C (es)
CO (1) CO4970726A1 (es)
DZ (1) DZ2600A1 (es)
EA (1) EA002705B1 (es)
GT (1) GT199800134A (es)
HN (1) HN1998000124A (es)
HR (1) HRP980475A2 (es)
HU (1) HUP0003103A3 (es)
ID (1) ID24275A (es)
IL (2) IL133957A0 (es)
IS (1) IS5345A (es)
MA (1) MA26539A1 (es)
NO (1) NO20000999L (es)
NZ (1) NZ502283A (es)
OA (1) OA11289A (es)
PA (1) PA8457201A1 (es)
PE (1) PE106999A1 (es)
PL (1) PL339088A1 (es)
SA (1) SA98190432A (es)
SK (1) SK1392000A3 (es)
TN (1) TNSN98158A1 (es)
TR (1) TR200000562T2 (es)
UY (1) UY25159A1 (es)
WO (1) WO1999011263A1 (es)
YU (1) YU2700A (es)
ZA (1) ZA987843B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ252051A (en) 1992-05-19 1996-10-28 Graham Edmund Kelly Health supplement comprising a phyto-oestrogen selected from genistein, daidzein, biochanin and/or formononetin
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
AUPO203996A0 (en) 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
ATE242007T1 (de) 1998-12-23 2003-06-15 Searle Llc Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
EP1076091A1 (en) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
AUPQ266199A0 (en) 1999-09-06 1999-09-30 Novogen Research Pty Ltd Compositions and therapeutic methods involving isoflavones and analogues thereof
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
AUPR363301A0 (en) 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
EP1465885A4 (en) 2002-01-17 2005-04-27 Pharmacia Corp NOVEL ALKYL / ARYL HYDROXY OR CETOTHIEPINE COMPOUNDS AS INHIBITORS OF BILIARY ACID TRANSPORT OF THE ILEAL TYPE AND ABSORPTION OF TAUROCHOLATE
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005097191A2 (en) * 2004-04-04 2005-10-20 Sepracor Inc. COMBINATIONS COMPRISING (S)- AMLODIPINE AND A HMG-CoA REDUCTASE INHIBITOR OR CHOLESTEROL ABSORPOTION INHIBITOR OR BOTH, AND METHODS FOR REDUCING HYPERTENSION
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
KR100742432B1 (ko) 2005-12-27 2007-07-24 한미약품 주식회사 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
CA2645281A1 (en) 2006-03-29 2007-10-04 Kowa Co., Ltd. Triglyceride-lowering agent and hyperinsulinism-ameliorating agent
WO2008023958A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
MX2007008440A (es) * 2007-07-11 2009-02-18 Senosiain S A De C V Lab Composicion farmaceutica combinada.
KR20090091083A (ko) * 2008-02-22 2009-08-26 한올제약주식회사 방출성이 제어된 심혈관계질환 치료용 약제학적 제제
WO2009125987A2 (ko) * 2008-04-10 2009-10-15 한올제약주식회사 약제학적 제제
KR20100008356A (ko) * 2008-07-15 2010-01-25 한올제약주식회사 칼슘채널길항제를 포함하는 약제학적 제제
CN101804055B (zh) * 2010-04-27 2012-01-25 施慧达药业集团(吉林)有限公司 复方药物制剂
US20190263888A1 (en) 2010-10-19 2019-08-29 Op-T Llc Therapeutic peptides and methods for treating autoimmune related disease
TN2017000344A1 (en) 2015-02-06 2019-01-16 Intercept Pharmaceuticals Inc Pharmaceutical compositions for combination therapy
EP3706799B8 (en) * 2017-11-10 2025-04-23 Op-T Llc Peptide for preventing, modulating and/or reducing cardiovascular disease
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
US12377045B2 (en) 2019-11-25 2025-08-05 Fordoz Pharma Corp. Oral liquid formulations of lipid-lowering and blood pressure-lowering drugs
EP4135742A2 (en) 2020-04-17 2023-02-22 Op-T Llc Bioactive peptides and methods of use thereof
CN112826937B (zh) * 2021-03-25 2022-03-22 山东大学齐鲁医院 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN176897B (es) * 1993-10-29 1996-09-28 Cadila Lab Ltd
DE19539363A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von festen Arzneiformen

Also Published As

Publication number Publication date
CA2296726C (en) 2004-06-29
PL339088A1 (en) 2000-12-04
IL133957A (en) 2006-06-11
ZA987843B (en) 2000-02-28
CA2296726A1 (en) 1999-03-11
HRP980475A2 (en) 1999-06-30
SA98190432A (ar) 2005-12-03
OA11289A (en) 2003-08-25
HK1029530A1 (en) 2001-04-06
HN1998000124A (es) 1999-02-09
EP1003507A1 (en) 2000-05-31
IS5345A (is) 2000-01-14
PA8457201A1 (es) 2000-05-24
GT199800134A (es) 2000-02-08
WO1999011263A1 (en) 1999-03-11
DZ2600A1 (fr) 2003-03-01
UY25159A1 (es) 2000-12-29
HUP0003103A2 (hu) 2001-01-29
AR017514A1 (es) 2001-09-12
NZ502283A (en) 2002-05-31
MA26539A1 (fr) 2004-12-20
CN1117566C (zh) 2003-08-13
TR200000562T2 (tr) 2000-08-21
NO20000999D0 (no) 2000-02-28
YU2700A (sh) 2002-06-19
CN1268054A (zh) 2000-09-27
NO20000999L (no) 2000-02-28
SK1392000A3 (en) 2000-08-14
TNSN98158A1 (fr) 2005-03-15
AP9801333A0 (en) 1998-09-30
BR9811558A (pt) 2000-08-22
HUP0003103A3 (en) 2002-03-28
ID24275A (id) 2000-07-13
AU744982B2 (en) 2002-03-07
CO4970726A1 (es) 2000-11-07
EA200000013A1 (ru) 2000-08-28
AU8458598A (en) 1999-03-22
BG104076A (en) 2000-09-29
US20020025981A1 (en) 2002-02-28
EA002705B1 (ru) 2002-08-29
AP1207A (en) 2003-09-20
IL133957A0 (en) 2001-04-30
JP2001514224A (ja) 2001-09-11
KR20010022385A (ko) 2001-03-15

Similar Documents

Publication Publication Date Title
PE106999A1 (es) Composicion de amlodipina y una estatina
AR018777A1 (es) Composicion farmaceutica que contiene una combinacion de una estatina y aspirina y metodo.
MX2009003920A (es) Estatina y acidos grasos omega 3 para reducir los niveles de apo b.
EA200970359A1 (ru) Статин и омега-3 жирные кислоты для снижения уровней аро-в
ECSP085573A (es) COMPOSICIÓN QUE COMPRENDE UN INHIBIDOR DE LA ABSORCOMPOSICIÓN QUE COMPRENDE UN INHIBIDOR DE LA ABSORCIÓN DEL COLESTEROL, UN INHIBIDOR DE HMG-CoA REDUCCIÓN DEL COLESTEROL, UN INHIBIDOR DE HMG-CoA REDUCTASA Y UN AGENTE ESTABILIZANTE TASA Y UN AGENTE ESTABILIZANTE
PT97660A (pt) Processo para a preparacao de composicoes farmaceuticas contendo um agente hipocolesterolizante e um inibidor da enzima de conversao da angiotensina
IE970731A1 (en) Product and method for the treatment of hyperlipidemia
AR095182A1 (es) Composiciones de estatinas y ácidos grasos omega-3
NO20056152L (no) Nitrooksyderivater av fluvastatin, pravastatin, cerivastatin, atorvastatin og rosuvastatin som kolesterolreduserende midler med bedret anti-inflammatorisk, antitrombotisk og antiblodplatevirkende aktivitet
CO6311069A2 (es) Cápsulas que comprenden ácido acetilsalicílico, un inhibidor de la hmg-coa reductasa y un ace inhibidor para la prevención de enfermedades cardiovasculares
PE20050148A1 (es) Combinacion que comprende 2-metilpropanotioato de s-[2-({[1-(2-etilbutil)ciclohexil]carbonil}amino)fenilo] y un inhibidor de hmg coa reductasa
BR9813542A (pt) Combinações de estatina-éter carboxialquìlico
PE20020323A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)
PE55694A1 (es) Medicamentos
ECSP992883A (es) Composicion farmaceutica que contiene una combinacion de una estatina y aspirina y metodo
AR048668A1 (es) Composiciones hipocolesterolemiantes y procedimiento para prepararlas
RU2007148908A (ru) Составы для снижения риска возникновения вызванной лекарственными средствами аритмии
PE20000348A1 (es) Composicion farmaceutica que comprende un inhibidor de metaloproteasa de matriz (mmp) y una estatina
PE20090439A1 (es) Composicion farmaceutica combinada que contiene besilato de amlodipino y pravastatina sodica
BR9813539A (pt) Combinações de inibidor de lp(a) e estatina anti-hiperlipidêmicas
PE20040623A1 (es) Combinacion de antagonista de nmda con inhibidores de la acetilcolina esterasa
CA2375378A1 (en) Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines
ES2061942T3 (es) Composicion farmaceutica util para el tratamiento de enfermedades cardiovasculares.
RU2017120028A (ru) Фармацевтическая композиция для лечения гиперлипидимии
DE60025344D1 (de) Synergistische wirkungen von amlodipin und dem hydroxylierten metabolit von atorvastatin

Legal Events

Date Code Title Description
FC Refusal